Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- Study finds 50 noncancer drugs also fight canceron February 2, 2020 at 1:00 am
It turns out some approved, safe drugs have unexpected anticancer properties. Share on Pinterest Some existing non-oncology drugs may also have the ability to fight cancer. Occasionally, researchers ...
- This anticancer drug could help treat common heart failureon February 1, 2020 at 3:16 am
In a new study, researchers found that a common form of heart failure could be treated with an already approved anticancer drug. The research was conducted by scientists at the Lewis Katz School of ...
- Pre-existing anticancer drug could help treat common form of heart failureon January 29, 2020 at 2:35 pm
When it comes to finding new treatments for disease, reinventing the wheel is not always necessary - drugs already in use for other conditions may do the job. And if it turns out that a pre-existing ...
- Common form of heart failure could be treated with already approved anticancer drugon January 29, 2020 at 9:36 am
When it comes to finding new treatments for disease, reinventing the wheel is not always necessary—drugs already in use for other conditions may do the job. And if it turns out that a pre-existing ...
- Towards better anti-cancer drugs: New insights into CDK8, an important human oncogeneon January 28, 2020 at 9:20 am
Misregulated CDK8 is an important factor in the development of colon, breast and skin cancer. Hence, in recent years considerable efforts have been undertaken to develop drugs that specifically target ...
- Towards better anti-cancer drugson January 28, 2020 at 7:27 am
Hence, in recent years considerable efforts have been undertaken to develop drugs that specifically target CDK8 and that do not affect other molecules that are closely related to CDK8, but are ...
- Anticancer Drugs Market Analysis By Stage Of Development | F. Hoffmann-La Roche, Eli Lilly and Company, CELGENEon January 27, 2020 at 3:23 am
Global Anticancer Drugs Market Insights, Forecast to 2025 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with ...
- Chemotherapy Induced Anemia Drug Market With Robust CAGR in Forecast Period 2019 to 2026on January 26, 2020 at 10:09 pm
Ameco Research announced the latest market research report on “Global Chemotherapy Induced Anemia Drug Market: Global Industry Size, Share, Trends and Forecast, 2019-2026". In a latest study on the ...
- A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screeningon January 23, 2020 at 2:11 am
Accurate quantification of drug effects is crucial for identifying pharmaceutically actionable cancer vulnerabilities. Current cell viability-based measurements often lead to biased response estimates ...
via Bing News